A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal Consta Following a Single Intramuscular Injection at 25 mg or 50 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder

Trial Profile

A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal Consta Following a Single Intramuscular Injection at 25 mg or 50 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2015

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Luye Pharma Group
  • Most Recent Events

    • 17 Jun 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 03 Mar 2015 Planned End Date changed from 1 Nov 2014 to 1 May 2015 according to ClinicalTrials.gov record.
    • 03 Mar 2015 Planned primary completion date changed from 1 Nov 2014 to 1 May 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top